Kimberley T Lee1,2, Lisa Jacobs3, Elaine M Walsh4, Vered Stearns4, Jodi B Segal5,6. 1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans St, Baltimore, MD, USA. klee149@jhmi.edu. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. klee149@jhmi.edu. 3. Division of Surgical Oncology, Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA. 4. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans St, Baltimore, MD, USA. 5. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
PURPOSE: Delays in initiating adjuvant endocrine therapy (AET) are a cause for concern among women with breast cancer and clinicians, but the impact of delayed AET on overall survival (OS) is unclear. This study seeks to describe the relationship between delayed AET and OS. METHODS: Retrospective cohort study of women with stage II and III hormone receptor positive, human epidermal receptor 2 negative, invasive breast cancer, identified from the National Cancer Database. The primary exposure delayed AET, was defined as initiation of AET more than 12 months after breast cancer diagnosis. Using logistic regression, we examined predictors of delayed AET. The survival analysis with Cox proportional hazards regression adjusted for patient, tumor, and treatment characteristics. RESULTS: Among the 391,594 included women, 12,162 (3.1%) had delayed AET. Predictors of delayed AET included Black race (adjusted odds ratio [aOR] = 1.61, 95% confidence interval [CI] 1.52-1.70) or Hispanic ethnicity (aOR = 1.25, 95% CI 1.16-1.35) vs white race, Medicare (aOR = 1.13, 95% CI 1.06-1.20) or Medicaid (aOR = 1.41, 95% CI 1.32-1.50) versus private insurance, and cancer stage III (aOR = 1.24, 95% CI 1.19-1.30) vs stage II. With median follow-up of 67.4 months, 67,335 (17.2%) patients died. Delayed AET had no statistically significant effect on the hazard of death (adjusted hazards ratio = 1.01; 95% CI 0.96-1.06) compared to initiation within 12 months of diagnosis. CONCLUSION: This study suggests that there may be no adverse impact on survival if initiation of AET occurs 12 to 24 months after initial diagnosis compared to within 12 months of diagnosis as currently recommended.
PURPOSE: Delays in initiating adjuvant endocrine therapy (AET) are a cause for concern among women with breast cancer and clinicians, but the impact of delayed AET on overall survival (OS) is unclear. This study seeks to describe the relationship between delayed AET and OS. METHODS: Retrospective cohort study of women with stage II and III hormone receptor positive, human epidermal receptor 2 negative, invasive breast cancer, identified from the National Cancer Database. The primary exposure delayed AET, was defined as initiation of AET more than 12 months after breast cancer diagnosis. Using logistic regression, we examined predictors of delayed AET. The survival analysis with Cox proportional hazards regression adjusted for patient, tumor, and treatment characteristics. RESULTS: Among the 391,594 included women, 12,162 (3.1%) had delayed AET. Predictors of delayed AET included Black race (adjusted odds ratio [aOR] = 1.61, 95% confidence interval [CI] 1.52-1.70) or Hispanic ethnicity (aOR = 1.25, 95% CI 1.16-1.35) vs white race, Medicare (aOR = 1.13, 95% CI 1.06-1.20) or Medicaid (aOR = 1.41, 95% CI 1.32-1.50) versus private insurance, and cancer stage III (aOR = 1.24, 95% CI 1.19-1.30) vs stage II. With median follow-up of 67.4 months, 67,335 (17.2%) patientsdied. Delayed AET had no statistically significant effect on the hazard of death (adjusted hazards ratio = 1.01; 95% CI 0.96-1.06) compared to initiation within 12 months of diagnosis. CONCLUSION: This study suggests that there may be no adverse impact on survival if initiation of AET occurs 12 to 24 months after initial diagnosis compared to within 12 months of diagnosis as currently recommended.
Authors: John M McLaughlin; Roger T Anderson; Amy K Ferketich; Eric E Seiber; Rajesh Balkrishnan; Electra D Paskett Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Amy Brazda; Jordan Estroff; David Euhus; A Marilyn Leitch; James Huth; Valerie Andrews; Amy Moldrem; Roshni Rao Journal: Ann Surg Oncol Date: 2010-09-19 Impact factor: 5.344
Authors: Dawn L Hershman; Xiaoyan Wang; Russell McBride; Judith S Jacobson; Victor R Grann; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2006-04-01 Impact factor: 4.872
Authors: Harold J Burstein; Christina Lacchetti; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen A Gelmon; Sharon H Giordano; Clifford A Hudis; Alexander J Solky; Vered Stearns; Eric P Winer; Jennifer J Griggs Journal: J Clin Oncol Date: 2018-11-19 Impact factor: 44.544
Authors: Richard J Bleicher; Karen Ruth; Elin R Sigurdson; J Robert Beck; Eric Ross; Yu-Ning Wong; Sameer A Patel; Marcia Boraas; Eric I Chang; Neal S Topham; Brian L Egleston Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Dong Wook Shin; Juhee Cho; So Young Kim; Eliseo Guallar; Seung Sik Hwang; Belong Cho; Jae Hwan Oh; Ki Wook Jung; Hong Gwan Seo; Jong Hyock Park Journal: Ann Surg Oncol Date: 2013-03-26 Impact factor: 5.344
Authors: Paul E Goss; James N Ingle; Kathleen I Pritchard; Nicholas J Robert; Hyman Muss; Julie Gralow; Karen Gelmon; Tim Whelan; Kathrin Strasser-Weippl; Sheldon Rubin; Keren Sturtz; Antonio C Wolff; Eric Winer; Clifford Hudis; Alison Stopeck; J Thaddeus Beck; Judith S Kaur; Kate Whelan; Dongsheng Tu; Wendy R Parulekar Journal: N Engl J Med Date: 2016-06-05 Impact factor: 91.245